In neuroblastoma, TP53 mutations are rare at diagnosis, however aberrations in the p53 pathway are observed more frequently at relapse (59–62), where around 50% of relapsed cases analyzed show TP53 mutation, MDM2 amplification or p14ARF inactivation, suggesting that p53 inactivation could be a contributor to acquired drug resistance. This evidence concerns the gene TP53 and neuroblastoma.